Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, as stated in their Registration Statement on Form F-3 filed on April 1, 2024. In a letter dated April 12, 2024, Apollomics clarified that the majority of its operations are not conducted in China but through its wholly-owned subsidiary in California, with its business headquarters and management team based in the United States. The company also highlighted that most of its research and development, including clinical trials, are conducted outside of China, particularly in the United States and Australia. Apollomics maintains that less than 20% of its R&D efforts and expenses are related to its operations in Hong Kong and mainland China, where it has two wholly-owned subsidiaries. The company further stated that the majority of its cash and expenditures are held and incurred outside of China, reinforcing that its primary operations are not China-centric.

Apollomics Inc., a biopharmaceutical company, has responded to a comment from the SEC regarding its operations in China. The SEC's Division of Corporation Finance had requested clarification on the extent of Apollomics' operations in China, as stated in their Registration Statement on Form F-3 filed on April 1, 2024. In a letter dated April 12, 2024, Apollomics clarified that the majority of its operations are not conducted in China but through its wholly-owned subsidiary in California, with its business headquarters and management team based in the United States. The company also highlighted that most of its research and development, including clinical trials, are conducted outside of China, particularly in the United States and Australia. Apollomics maintains that less than 20% of its R&D efforts and expenses are related to its operations in Hong Kong and mainland China, where it has two wholly-owned subsidiaries. The company further stated that the majority of its cash and expenditures are held and incurred outside of China, reinforcing that its primary operations are not China-centric.